Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + dexamethasone + cyclophosphamide vs carfilzomib + dexamethasone in relapsed/refractory multiple myeloma
2016-005008-24Phase 2Active
- Sponsor
- PETHEMA
- Start
- Oct 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in multiple myeloma (MM) comparing Carfilzomib + dexamethasone + cyclophosphamide with Carfilzomib + dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started Oct 2017; status: active.
02
Drugs
carfilzomibdexamethasonecyclophosphamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-005008-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005008-24.